Arnigen 49 mg+51 mg (Tablet)
Unit Price: ৳ 85.00 (2 x 10: ৳ 1,700.00)
Strip Price: ৳ 850.00
Medicine Details
| Category | Details |
|---|---|
| Generic | Sacubitril valsartan |
| Company | General pharmaceuticals ltd |
| Also available as |
Indications
- Reduces risk of cardiovascular death and hospitalization for heart failure in chronic heart failure patients
- Treats symptomatic heart failure with systemic left ventricular systolic dysfunction in pediatric patients
- Administered in conjunction with other heart failure therapies
- Used in place of an ACE inhibitor or other ARB
Pharmacology
- Contains neprilysin inhibitor sacubitril and angiotensin receptor blocker valsartan
- Inhibits neprilysin via LBQ657, the active metabolite of sacubitril
- Blocks angiotensin II type-1 receptor via valsartan
- Increases levels of peptides degraded by neprilysin, such as natriuretic peptides, by LBQ657
- Simultaneously inhibits effects of angiotensin II by valsartan
Dosage & Administration
- Recommended starting dose for adults: 49/51 mg orally twice daily
- Target maintenance dose for adults: 97/103 mg twice daily
- Adjusted starting dose for pediatric patients based on weight
- Recommended dose titration for pediatric patients
Interaction
- Should not be used with ACEi, aliskiren in diabetic patients, or concomitantly with an ARB
- Potassium-sparing diuretics may increase serum potassium level
- NSAIDs may increase risk of renal impairment
- Increased risk of lithium toxicity with lithium
Contraindications
- Hypersensitivity to any component
- History of angioedema related to previous ACE inhibitor or ARB therapy
- Concomitant use of ACE inhibitors
- Concomitant use of aliskiren in diabetic patients
Side Effects
- Angioedema
- Hypotension
- Impaired renal function
- Hyperkalemia
- Cough
- Dizziness
Pregnancy & Lactation
- Safety and effectiveness not established in pediatric patients below 1 year
- No relevant pharmacokinetic differences observed in elderly patients
- No dose adjustment required for mild hepatic impairment
- Not recommended in patients with severe hepatic impairment
- No dose adjustment required in patients with mild to moderate renal impairment
- Recommended starting dose in severe renal impairment: 24/26 mg twice daily
Precautions & Warnings
- May cause angioedema
- Lower blood pressure and may cause symptomatic hypotension
- Monitor serum creatinine and renal function
- Monitor serum potassium periodically and treat appropriately
- Dosage reduction or interruption may be required
Use in Special Populations
- Safety and effectiveness not established in pediatric patients
- No relevant pharmacokinetic differences observed in elderly patients
- No starting dose adjustment needed for mild or moderate renal impairment
- Recommended starting dose for severe renal impairment: 24/26 mg twice daily
- Recommended starting dose for moderate hepatic impairment: 24/26 mg twice daily
- Not recommended in patients with severe hepatic impairment
Overdose Effects
- Limited data available for overdosage
- Hypotension likely result of overdosage
- Symptomatic treatment should be provided
- Unlikely to be removed by hemodialysis
Storage Conditions
- Keep in a dry place
- Store below 30°C
- Protect from moisture
- Keep out of the reach of children